+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mycoplasma Testing Market By Product, By Technology, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 400 Pages
  • April 2023
  • Region: Global
  • Allied Market Research
  • ID: 5835825
Description Jump to:
The Mycoplasma Testing Market was valued at $0.7 billion in 2022 and is estimated to reach $2.24 Billion by 2032, exhibiting a CAGR of 11.7% from 2023 to 2032.

Mycoplasma testing is used to detect the presence of mycoplasma contamination in cell culture samples. Mycoplasma is a type of bacteria that lacks a cell wall and is difficult to detect and remove from cell cultures. Mycoplasma contamination can cause various problems in cell cultures, such as altered growth characteristics, changes in gene expression, and compromised experimental results. Therefore, it is essential to regularly test cell cultures for mycoplasma contamination to ensure the accuracy and reliability of experimental results. Mycoplasma testing is important in the process of testing vaccines, virus cultures, and other biopharmaceuticals.

The mycoplasma testing market growth is driven by an increase in demand for biologics & biosimilars, a surge in incidences of cell culture contamination, and a rise in the adoption of novel technologies for drug development. Biologics and biosimilars are complex drugs produced using living cells, and they can be contaminated by mycoplasma during the manufacturing process. Thus, regulatory bodies such as Food and Drug Administration (FDA) and European Medicines Agency (EMA) require biologics and biosimilars to be tested for mycoplasma contamination before they are approved for use. This has created a surge in demand for mycoplasma testing services. For instance, according to the IQVIA report on the Impact of Biosimilar Competition in Europe in 2021, about 9 biosimilars were approved in 2020 and 7 approved in 2021. Thus, the rise in the approval and demand for biologics & biosimilars has resulted in increased demand for mycoplasma testing.

Furthermore, the rise in incidences of cell culture contamination in the biopharmaceutical industry and the globalization of clinical trials are the key factors that boost market growth. As clinical trials are conducted across multiple countries and regions, there is a need for mycoplasma testing services that can ensure the safety of trial participants and the accuracy of trial data. This has led to an increasing demand for mycoplasma testing services and products that meet standardized testing requirements.

However, the high cost of mycoplasma testing products limits their adoption in biopharmaceutical companies, which, in turn, restrains the market growth. For instance, the cost of SouthernBiotech’s Mycoplasma Detection Kit used for the detection of mycoplasma contamination in cell cultures is around $200-230. In addition, the price of culture-based mycoplasma testing service is about $250-300 per sample. Thus, the high cost of mycoplasma testing products and services negatively impacts market growth.

On the other hand, the increase in demand for mycoplasma testing in developed and developing countries such as U.S., Germany, and China is expected to create immense opportunities for the mycoplasma testing market during the forecast period.

The mycoplasma testing market is segmented on the basis of product, technology, application, end-user, and region. On the basis of product, the market is categorized into instruments, kits & reagents, and services. On the basis of technology, the market is divided into PCR, ELISA, microbial culture techniques, and enzymatic methods. On the basis of application, the market is classified into cell line testing, virus testing, end-of-production cell testing, and others. On the basis of end users, the market is segregated into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global mycoplasma testing market are ATCC, Bionique Testing Laboratories LLC, Bio-Rad Laboratories, Inc., Charles River Laboratories, Eurofins Scientific, F. Hoffmann-La Roche Ltd., InvivoGen, Lonza, Norgen Biotek Corp., and Thermo Fisher Scientific Inc. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mycoplasma testing market analysis from 2022 to 2032 to identify the prevailing mycoplasma testing market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

An in-depth analysis of the mycoplasma testing market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes analysis of the regional as well as global mycoplasma testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Instruments
  • Kits and Reagents
  • Services

By Technology

  • PCR
  • ELISA
  • Microbial Culture Techniques
  • Enzymatic Methods

By Application

  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others

By End User

  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical and Biotechnology Companies
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • ATCC
  • Bionique Testing Laboratories LLC
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • InvivoGen
  • Lonza
  • Norgen Biotek Corp.
  • Thermo Fisher Scientific Inc.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in demand for mycoplasma testing
3.4.1.2. Increase in incidences of cell culture contamination
3.4.2. Restraints
3.4.2.1. High cost of mycoplasma testing kits and instruments
3.4.3. Opportunities
3.4.3.1. Developing economies offer lucrative opportunities
3.4.3.2. Rise in technological advancements
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MYCOPLASMA TESTING MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Kits and Reagents
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Services
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: MYCOPLASMA TESTING MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. PCR
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. ELISA
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Microbial Culture Techniques
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Enzymatic Methods
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: MYCOPLASMA TESTING MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cell Line Testing
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Virus Testing
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. End of Production Cells Testing
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: MYCOPLASMA TESTING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Academic Research Institutes
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Cell Banks
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Contract Research Organizations
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
7.5. Pharmaceutical and Biotechnology Companies
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by region
7.5.3. Market share analysis by country
7.6. Others
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by region
7.6.3. Market share analysis by country
CHAPTER 8: MYCOPLASMA TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product
8.2.3. Market size and forecast, by Technology
8.2.4. Market size and forecast, by Application
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product
8.2.6.1.3. Market size and forecast, by Technology
8.2.6.1.4. Market size and forecast, by Application
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product
8.2.6.2.3. Market size and forecast, by Technology
8.2.6.2.4. Market size and forecast, by Application
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product
8.2.6.3.3. Market size and forecast, by Technology
8.2.6.3.4. Market size and forecast, by Application
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product
8.3.3. Market size and forecast, by Technology
8.3.4. Market size and forecast, by Application
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product
8.3.6.1.3. Market size and forecast, by Technology
8.3.6.1.4. Market size and forecast, by Application
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product
8.3.6.2.3. Market size and forecast, by Technology
8.3.6.2.4. Market size and forecast, by Application
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product
8.3.6.3.3. Market size and forecast, by Technology
8.3.6.3.4. Market size and forecast, by Application
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product
8.3.6.4.3. Market size and forecast, by Technology
8.3.6.4.4. Market size and forecast, by Application
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product
8.3.6.5.3. Market size and forecast, by Technology
8.3.6.5.4. Market size and forecast, by Application
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product
8.3.6.6.3. Market size and forecast, by Technology
8.3.6.6.4. Market size and forecast, by Application
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product
8.4.3. Market size and forecast, by Technology
8.4.4. Market size and forecast, by Application
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product
8.4.6.1.3. Market size and forecast, by Technology
8.4.6.1.4. Market size and forecast, by Application
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product
8.4.6.2.3. Market size and forecast, by Technology
8.4.6.2.4. Market size and forecast, by Application
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product
8.4.6.3.3. Market size and forecast, by Technology
8.4.6.3.4. Market size and forecast, by Application
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product
8.4.6.4.3. Market size and forecast, by Technology
8.4.6.4.4. Market size and forecast, by Application
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product
8.4.6.5.3. Market size and forecast, by Technology
8.4.6.5.4. Market size and forecast, by Application
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product
8.4.6.6.3. Market size and forecast, by Technology
8.4.6.6.4. Market size and forecast, by Application
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product
8.5.3. Market size and forecast, by Technology
8.5.4. Market size and forecast, by Application
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product
8.5.6.1.3. Market size and forecast, by Technology
8.5.6.1.4. Market size and forecast, by Application
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product
8.5.6.2.3. Market size and forecast, by Technology
8.5.6.2.4. Market size and forecast, by Application
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product
8.5.6.3.3. Market size and forecast, by Technology
8.5.6.3.4. Market size and forecast, by Application
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product
8.5.6.4.3. Market size and forecast, by Technology
8.5.6.4.4. Market size and forecast, by Application
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Thermo Fisher Scientific Inc.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Charles River Laboratories
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Lonza
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. F. Hoffmann-La Roche Ltd.
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bio-Rad Laboratories, Inc.
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Eurofins Scientific
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. ATCC
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Bionique Testing Laboratories LLC
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.9. InvivoGen
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.10. Norgen Biotek Corp.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
List of Tables
TABLE 01. GLOBAL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. MYCOPLASMA TESTING MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 06. MYCOPLASMA TESTING MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
TABLE 07. MYCOPLASMA TESTING MARKET FOR ELISA, BY REGION, 2022-2032 ($MILLION)
TABLE 08. MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY REGION, 2022-2032 ($MILLION)
TABLE 09. MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 11. MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 12. MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 13. MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 14. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 20. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. MYCOPLASMA TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 27. U.S. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 28. U.S. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 29. U.S. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. U.S. MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 31. CANADA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 32. CANADA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 33. CANADA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 34. CANADA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 35. MEXICO MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 36. MEXICO MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 37. MEXICO MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. MEXICO MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 40. EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 41. EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. EUROPE MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 44. GERMANY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 45. GERMANY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 46. GERMANY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. GERMANY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. FRANCE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 49. FRANCE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 50. FRANCE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. FRANCE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. UK MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 53. UK MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 54. UK MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. UK MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 56. ITALY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 57. ITALY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 58. ITALY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. ITALY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 60. SPAIN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 61. SPAIN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 62. SPAIN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. SPAIN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 66. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 73. JAPAN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 74. JAPAN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 75. JAPAN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. JAPAN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. CHINA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. CHINA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 79. CHINA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. CHINA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 81. AUSTRALIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 82. AUSTRALIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 85. INDIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 86. INDIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 87. INDIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. INDIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 90. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 91. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 95. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 97. LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 98. LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 99. LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 100. LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 101. LAMEA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 102. BRAZIL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 103. BRAZIL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 104. BRAZIL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. BRAZIL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 106. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 110. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 111. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 112. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 113. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 115. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
TABLE 116. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 117. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 118. THERMO FISHER SCIENTIFIC INC. : KEY EXECUTIVES
TABLE 119. THERMO FISHER SCIENTIFIC INC. : COMPANY SNAPSHOT
TABLE 120. THERMO FISHER SCIENTIFIC INC. : PRODUCT SEGMENTS
TABLE 121. THERMO FISHER SCIENTIFIC INC. : SERVICE SEGMENTS
TABLE 122. THERMO FISHER SCIENTIFIC INC. : PRODUCT PORTFOLIO
TABLE 123. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
TABLE 124. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 125. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
TABLE 126. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
TABLE 127. LONZA: KEY EXECUTIVES
TABLE 128. LONZA: COMPANY SNAPSHOT
TABLE 129. LONZA: PRODUCT SEGMENTS
TABLE 130. LONZA: SERVICE SEGMENTS
TABLE 131. LONZA: PRODUCT PORTFOLIO
TABLE 132. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 133. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 134. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 135. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 136. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
TABLE 137. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
TABLE 138. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
TABLE 139. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
TABLE 140. EUROFINS SCIENTIFIC: KEY EXECUTIVES
TABLE 141. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 142. EUROFINS SCIENTIFIC: SERVICE SEGMENTS
TABLE 143. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 144. ATCC: KEY EXECUTIVES
TABLE 145. ATCC: COMPANY SNAPSHOT
TABLE 146. ATCC: PRODUCT SEGMENTS
TABLE 147. ATCC: SERVICE SEGMENTS
TABLE 148. ATCC: PRODUCT PORTFOLIO
TABLE 149. BIONIQUE TESTING LABORATORIES LLC: KEY EXECUTIVES
TABLE 150. BIONIQUE TESTING LABORATORIES LLC: COMPANY SNAPSHOT
TABLE 151. BIONIQUE TESTING LABORATORIES LLC: PRODUCT SEGMENTS
TABLE 152. BIONIQUE TESTING LABORATORIES LLC: SERVICE SEGMENTS
TABLE 153. BIONIQUE TESTING LABORATORIES LLC: PRODUCT PORTFOLIO
TABLE 154. INVIVOGEN: KEY EXECUTIVES
TABLE 155. INVIVOGEN: COMPANY SNAPSHOT
TABLE 156. INVIVOGEN: PRODUCT SEGMENTS
TABLE 157. INVIVOGEN: SERVICE SEGMENTS
TABLE 158. INVIVOGEN: PRODUCT PORTFOLIO
TABLE 159. NORGEN BIOTEK CORP.: KEY EXECUTIVES
TABLE 160. NORGEN BIOTEK CORP.: COMPANY SNAPSHOT
TABLE 161. NORGEN BIOTEK CORP.: PRODUCT SEGMENTS
TABLE 162. NORGEN BIOTEK CORP.: SERVICE SEGMENTS
TABLE 163. NORGEN BIOTEK CORP.: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. MYCOPLASMA TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF MYCOPLASMA TESTING MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN MYCOPLASMA TESTING MARKET (2023-2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
FIGURE 08. HIGH INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMYCOPLASMA TESTING MARKET
FIGURE 10. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR SERVICES, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR PCR, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ELISA, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. MYCOPLASMA TESTING MARKET, BY END USER, 2022(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 30. MYCOPLASMA TESTING MARKET BY REGION, 2022
FIGURE 31. U.S. MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 32. CANADA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 33. MEXICO MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 34. GERMANY MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 35. FRANCE MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 36. UK MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 37. ITALY MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 38. SPAIN MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF EUROPE MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 40. JAPAN MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 41. CHINA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 42. AUSTRALIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 43. INDIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 44. SOUTH KOREA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 45. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 46. BRAZIL MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 47. SAUDI ARABIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 48. SOUTH AFRICA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 49. REST OF LAMEA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 54. COMPETITIVE DASHBOARD
FIGURE 55. COMPETITIVE HEATMAP: MYCOPLASMA TESTING MARKET
FIGURE 56. TOP PLAYER POSITIONING, 2022
FIGURE 57. THERMO FISHER SCIENTIFIC INC. : NET REVENUE, 2019-2021 ($MILLION)
FIGURE 58. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 59. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY REGION, 2021 (%)
FIGURE 60. CHARLES RIVER LABORATORIES: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 61. CHARLES RIVER LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 62. CHARLES RIVER LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 63. LONZA: NET SALES, 2019-2021 ($MILLION)
FIGURE 64. LONZA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 65. LONZA: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 66. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 69. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
FIGURE 70. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 71. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
FIGURE 72. EUROFINS SCIENTIFIC: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 73. EUROFINS SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2021 (%)

Companies Mentioned

  • ATCC
  • Bionique Testing Laboratories LLC
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • InvivoGen
  • Lonza
  • Norgen Biotek Corp.
  • Thermo Fisher Scientific Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Global Mycoplasma Testing Market by Product & Service (Assays, Kits, & Reagents, Instruments, Services), Technique (Enzyme-Linked Immunosorbent Assay, Nucleic Acid Testing, Staining), Application, End-User - Forecast 2024-2030 - Product Image

Global Mycoplasma Testing Market by Product & Service (Assays, Kits, & Reagents, Instruments, Services), Technique (Enzyme-Linked Immunosorbent Assay, Nucleic Acid Testing, Staining), Application, End-User - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Mycoplasma Testing Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030 - Product Image

Mycoplasma Testing Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030

  • Report
  • 146 Pages
  • Global
From
Mycoplasma Testing Kits & Reagents Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Mycoplasma Testing Kits & Reagents Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 103 Pages
  • Global
From
Mycoplasma Testing Global Market Report 2024 - Product Image

Mycoplasma Testing Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Mycoplasma Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Mycoplasma Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.